Sorafenib inhibited both the rise in TGFβ1 and collagen in cardiac tissue, thus preventing the essential component of left ventricular hypertrophy, i.e. interstitial collagen deposition. This evidence concerns the gene TGFB1 and left ventricular hypertrophy.